Drug:
Reaction: DERMATITIS ATOPIC
20250101 - 20251231
No. 601 - 700
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 601 | 25091436 |
US |
73 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 602 | 25091448 |
US |
35 | 1 |
Dermatitis atopic, Pruritus, Skin swelling, Ocular hyperaemia, Injection site pain, Injection site swelling, |
||||
DUPILUMAB, |
||||
| 603 | 25091450 |
US |
7 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 604 | 25091466 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 605 | 25091472 |
US |
74 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 606 | 25091498 |
US |
65 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 607 | 25091506 |
US |
39 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 608 | 25091507 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 609 | 25091514 |
US |
69 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 610 | 25091527 |
US |
17 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 611 | 25091530 |
US |
35 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 612 | 25091537 |
US |
3 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 613 | 25091538 |
US |
65 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 614 | 25091553 |
US |
2 | |
Dermatitis atopic, Pain, Eczema weeping, Musculoskeletal stiffness, Peripheral swelling, Wound, Skin warm, |
||||
DUPILUMAB, |
||||
| 615 | 25091558 |
US |
46 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 616 | 25091561 |
US |
62 | 2 |
Lethargy, Headache, Eye irritation, Dermatitis atopic, Rash, Burning sensation, Intentional product misuse, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 617 | 25091580 |
US |
52 | 2 |
Hypoaesthesia, Pain, Paraesthesia, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 618 | 25091587 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 619 | 25091600 |
US |
31 | 2 |
Rash erythematous, Pruritus, Skin burning sensation, Dermatitis, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 620 | 25091604 |
US |
57 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 621 | 25091624 |
US |
47 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 622 | 25091626 |
US |
36 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 623 | 25091628 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 624 | 25091637 |
US |
52 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 625 | 25091638 |
US |
55 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 626 | 25091642 |
US |
73 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 627 | 25091647 |
US |
37 | 2 |
Dermatitis atopic, Erythema, Rash, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 628 | 25091649 |
US |
65 | 2 |
Dermatitis atopic, Pruritus, Rash, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 629 | 25091655 |
US |
1 | |
Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 630 | 25091657 |
US |
37 | 1 |
Dermatitis atopic, Hypersensitivity, |
||||
DUPILUMAB, |
||||
| 631 | 25091665 |
US |
2 | |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 632 | 25091678 |
US |
71 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 633 | 25091685 |
US |
49 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 634 | 25091692 |
US |
2 | |
Stress, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 635 | 25091693 |
US |
47 | 2 |
Dermatitis atopic, Arthralgia, |
||||
DUPILUMAB, |
||||
| 636 | 25091700 |
US |
1 | |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 637 | 25091705 |
US |
63 | 2 |
Dermatitis atopic, Dry skin, Skin fissures, |
||||
DUPILUMAB, |
||||
| 638 | 25091724 |
US |
55 | 1 |
Rhinorrhoea, Dyspnoea, Eye pruritus, Dermatitis atopic, Hypersensitivity, |
||||
DUPILUMAB, |
||||
| 639 | 25091725 |
US |
10 | 1 |
Dermatitis atopic, Nasopharyngitis, |
||||
DUPILUMAB, |
||||
| 640 | 25091727 |
US |
43 | 2 |
Pain, Nausea, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 641 | 25091735 |
US |
51 | 2 |
Dermatitis atopic, Rash, Pruritus, Erythema, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 642 | 25091737 |
US |
46 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 643 | 25091744 |
US |
56 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 644 | 25091745 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 645 | 25091747 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 646 | 25091755 |
US |
62 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 647 | 25091788 |
US |
21 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 648 | 25091807 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 649 | 25091813 |
US |
30 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 650 | 25091880 |
CO |
1 | |
Subcutaneous abscess, Dermatitis atopic, Drug ineffective, |
||||
UPADACITINIB, |
||||
| 651 | 25082025 |
US |
1 | |
Stress, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 652 | 25082041 |
US |
52 | 2 |
Dermatitis atopic, Rash, Rash pruritic, |
||||
DUPILUMAB, |
||||
| 653 | 25082135 |
US |
17 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 654 | 25082196 |
US |
37 | 1 |
Stress, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 655 | 25082428 |
US |
53 | 2 |
Dermatitis atopic, Rash, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 656 | 25082462 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 657 | 25082687 |
US |
2 | |
Dermatitis atopic, Intentional product misuse, |
||||
DUPILUMAB, |
||||
| 658 | 25082711 |
US |
59 | 2 |
Rash pruritic, Condition aggravated, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 659 | 25082790 |
US |
53 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 660 | 25082910 |
US |
32 | 2 |
Dermatitis atopic, Rash macular, |
||||
DUPILUMAB, |
||||
| 661 | 25083067 |
US |
55 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 662 | 25083116 |
US |
32 | 1 |
Alopecia, Dermatitis atopic, Dandruff, |
||||
TRALOKINUMAB-LDRM, |
||||
| 663 | 25083227 |
US |
35 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 664 | 25083334 |
US |
40 | 2 |
Dermatitis atopic, Dry skin, |
||||
DUPILUMAB, |
||||
| 665 | 25083381 |
US |
40 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 666 | 25083484 |
US |
78 | 2 |
Injection site warmth, Injection site erythema, Dermatitis atopic, Pruritus, Rash erythematous, |
||||
DUPILUMAB, |
||||
| 667 | 25083503 |
US |
2 | |
Dermatitis atopic, Erythema, Dry skin, Pruritus, |
||||
DUPILUMAB, |
||||
| 668 | 25083706 |
US |
36 | 2 |
Fatigue, Dermatitis atopic, |
||||
DUPILUMAB, EPINEPHRINE, ADRENALINUM, RUXOLITINIB, CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE GEL USP, 1%, HYDROXYZINE, SPIRONOLACTONE, DOXYCYCLINE HYCLATE, DOXYCYCLINE, DOXYCLYCLINE HYCLATE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, PIMECROLIMUS, |
||||
| 669 | 25083748 |
US |
64 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 670 | 25084015 |
US |
2 | 1 |
Sleep disorder due to a general medical condition, Eye pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 671 | 25084020 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 672 | 25084022 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 673 | 25084261 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 674 | 25084578 |
US |
66 | 1 |
Dermatitis atopic, Dry skin, Skin wound, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 675 | 25084600 |
US |
32 | 1 |
Dermatitis atopic, Stress at work, |
||||
DUPILUMAB, |
||||
| 676 | 25084745 |
US |
2 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 677 | 25084781 |
US |
23 | 2 |
Multiple allergies, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 678 | 25084871 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, Therapeutic product ineffective, |
||||
DUPILUMAB, |
||||
| 679 | 25084970 |
US |
1 | |
Influenza, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 680 | 25085750 |
US |
65 | 1 |
Pruritus, Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 681 | 25085839 |
US |
30 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 682 | 25086063 |
US |
2 | |
Dermatitis atopic, |
||||
ABROCITINIB, |
||||
| 683 | 25086099 |
US |
63 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 684 | 25086175 |
US |
41 | 2 |
Dermatitis atopic, Surgery, |
||||
DUPILUMAB, |
||||
| 685 | 25081222 |
US |
57 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 686 | 25081228 |
US |
22 | 2 |
Urticaria cholinergic, Condition aggravated, Urticaria, Condition aggravated, Hyperhidrosis, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, CLOTRIMAZOLE, DRS. CLOTRIMAZOLE, FAMILY WELLNESS CLOTRIMAZOLE, CLOTRIMAZOLE TOPICAL, |
||||
| 687 | 25081233 |
US |
17 | 1 |
Dermatitis atopic, Rash erythematous, Pruritus, Skin burning sensation, Condition aggravated, |
||||
DUPILUMAB, |
||||
| 688 | 25081240 |
US |
19 | 2 |
Injection site pain, Dermatitis atopic, Dry skin, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 689 | 25081243 |
US |
30 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 690 | 25081271 |
US |
25 | 2 |
Dermatitis atopic, Rash pruritic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 691 | 25081295 |
US |
27 | 1 |
Dermatitis atopic, Pruritus, Dry skin, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 692 | 25081363 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 693 | 25081380 |
US |
51 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 694 | 25081419 |
US |
63 | 1 |
Dermatitis atopic, Pruritus, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 695 | 25081464 |
US |
84 | 1 |
Death, COVID-19, Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, DUPILUMAB, FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE ORAL, FEXOFENADINE HCL, MONTELUKAST, |
||||
| 696 | 25081490 |
US |
18 | 1 |
Sinus disorder, Dermatitis atopic, Therapeutic response unexpected, |
||||
DUPILUMAB, |
||||
| 697 | 25081502 |
US |
3 | 1 |
Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 698 | 25080481 |
US |
2 | |
Dermatitis atopic, Erythema, |
||||
DUPILUMAB, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, CHLORHEXIDINE GLUCONATE, ANTISEPTIC SKIN CLEANSER, |
||||
| 699 | 25080501 |
US |
19 | 2 |
Dermatitis atopic, Dry skin, |
||||
DUPILUMAB, |
||||
| 700 | 25080503 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28